Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its senior management will attend the annual meeting of the ASCO. The theme of this meeting is focused on bringing a difference in cancer care. Kenneth L. Waggoner, the CEO, reported that this year’s yearly meeting of ASCO will be most significant as they work towards registering the first patient in their planned clinical study in locally advanced pancreas cancer.
During this event, Pharmacyte will be planning a special meeting of major clinical oncologists who have shown interest in participating in its clinical study. This special meeting is intended to offer an update on the advancement company has made last year in getting set for the study; offer a timeline for submitting the IND and for registering the first patient; make introductions of and permit for comments by major members of company’s clinical management team, Dr. Matthias Löhr, Dr. Manuel Hidalgo, Translational Drug Development and Imaging Endpoints, the two prime CROs who will be performing the trial for company; and get a promise from the oncologists and their corresponding cancer centers to partake in exciting trial.
Joining Pharmacyte CEO will be Dr. Manuel Hidalgo, the main investigator for the study and Dr. Matthias Löhr, who is the Chairman of company’s Medical and Scientific Advisory Board. Other experts who will joining the team are Dr. Gerald W. Crabtree, the COO and Dr. Leonard Makowka, the Senior Strategic Advisor of the firm’s Board of Directors.
ASCO is one of the major firms in the world committed to the advancement of therapies for all types of cancer. Its yearly meeting is one of the largest scientific and educational meetings across the world. It brings over 30,000 oncology experts from across the world to discuss advanced treatment modalities, ongoing controversies and new therapies in the segment. Individuals from across the globe have enrolled for this year’s meeting with almost 50% of these from outside the U.S.